Non-invasive Prenatal Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Non-invasive Prenatal Testing Market is segmented by Component (Instruments, Kits, and Reagents, Services), Application (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Other Applications), End User (Hospitals, Diagnostic Labs), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The NIPT Industry Research Provides Value (in USD Billion) for the Above Segments.

Non-invasive Prenatal Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Non-invasive Prenatal Testing Market Size

Non-Invasive Prenatal Testing Market Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 3.90 Billion
Market Size (2030) USD 7.35 Billion
CAGR (2025 - 2030) 13.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Non-Invasive Prenatal Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Non-Invasive Prenatal Testing Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Non-invasive Prenatal Testing Market Analysis

The Non-Invasive Prenatal Testing Market is expected to register a CAGR of 13.5% during the forecast period.

Non-invasive prenatal testing (NIPT) and different test type is gaining prominence for its capability to assess the likelihood of certain congenital disabilities in unborn babies. NIPT, a cutting-edge advancement in prenatal diagnostics, utilizes methods such as next-generation sequencing and other high-throughput analysis tools to examine free placental DNA from maternal blood serum. Due to its advanced technologies and heightened accuracy, global demand and adoption rates of noninvasive prenatal testing are surging, a trend poised to propel market growth in the coming years.


As NIPT plays a crucial role in detecting chromosomal abnormalities, its rising demand is propelling market growth during the forecast period. For instance, as per the article published in January 2024 in Heliyon Journal, NIPT screening has the potential to enhance the detection of fetal sex chromosome abnormalities, copy number variation (CNVs), and other chromosomal issues while also reducing the false positive rate. Moreover, the detection rate of fetal sex chromosome abnormalities and overall chromosomal issues in pregnant women over 35 has seen a significant uptick, suggesting that advanced maternal age could be a risk factor for fetal chromosomal abnormalities. Hence, such studies highlight the benefits of NIPT, which accentuates the demand for the non-invasive prenatal screening market over the forecast period.


Furthermore, governments' increased support to conduct pre-natal testing for pregnant women across various nations is expected to potentially drive market growth rate in the coming years. For example, in April 2023, the Government of the Netherlands mentioned that all pregnant women can access the non-invasive prenatal test (NIPT) without needing to participate in a scientific study. This blood test screens for potential indicators of Down's syndrome, Edwards' syndrome, and Patau's syndrome in unborn children. NIPT is now integrated into standard prenatal screenings.


Similarly, various non-governmental organizations are collaborating with the government to reform the guidelines for prenatal testing, which is likely to promote market growth over the forecast period. For instance, in January 2023, Myriad Genetics, Inc., a frontrunner in genetic testing and precision medicine, voiced its endorsement of the latest guideline update from the American College of Medical Genetics and Genomics (ACMG). This update underscores the clinical significance of non-invasive prenatal screening (NIPS) in detecting various chromosomal abnormalities.


Overall, the increase in research activities showcasing the importance of NIPT, launches of prenatal screening programs, and the rise in strategic activities by the key players are expected to drive the non-invasive prenatal testing market during 2024 to 2029. However, a lack of skilled labor and stringent regulatory and ethical concerns are expected to hinder market growth over the forecast period.

Non-Invasive Prenatal Testing Industry Overview

The non-invasive prenatal testing industry is very competitive, with most players competing to maximize their market shares. Key players in the non-invasive prenatal testing market research are BGI, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., PerkinElmer Inc., Centogene NV, MedGenome Labs Ltd, Myriad Womens Health Inc., Qiagen. among others.


Currently, several major players, including market leaders, command a substantial share and a dominant stance in the market. These pivotal players emphasize technological innovations in their offerings, especially focusing on enhancing the market value of their products. Such concentrated endeavors are set to propel market growth in the foreseeable future.


For instance, in September 2023, TDL transitioned its NIPT testing from Harmony to the Illumina VeriSeq NIPT Solution v2. The Illumina VeriSeq NIPT Solution v2 analyzes the same conditions as Harmony, with added options for fetal sex and sex chromosome aneuploidies. Consequently, strategic product launches by key companies are set to drive market growth and influence market trends during the forecast period.

Non-invasive Prenatal Testing Market Leaders

  1. Centogene NV

  2. Eurofins Scientific

  3. PerkinElmer Inc

  4. BGI

  5. F. Hoffmann-La Roche Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
Non-Invasive Prenatal Testing Market Competitive Landscape
Need More Details on Market Players and Competiters?
Download PDF

Non-invasive Prenatal Testing Market News

  • October 2024: Yourgene Health, part of the Novacyt group of companies and a prominent player in the international molecular diagnostics arena, rolled out the inaugural non-invasive prenatal testing (NIPT) workflow in Colombia. This milestone took place at Genetix, a cutting-edge medical entity renowned for its expertise in human genetic diagnosis. Leveraging Yourgene’s IONA Nx NIPT Workflow, the service promises swift and precise NIPT results for expectant parents in Colombia, thereby mitigating turnaround delays and shipping challenges.
  • April 2024: BillionToOne, a molecular diagnostics firm dedicated to making powerful and precise tests universally accessible, achieved a significant milestone: testing over 80,000 patients for Rh incompatibility. This condition arises when a pregnant individual with Rh-negative blood carries a baby with Rh-positive blood. While rare, this incompatibility can result in a severe complication where the pregnant individual's immune system mistakenly targets the baby's red blood cells as foreign.
  • May 2024: Natera, Inc., a global frontrunner in cell-free DNA (cfDNA) and genetic testing, unveiled a novel cfDNA-based fetal RhD test. This launch is timely for the healthcare sector, as it aids physicians in patient care amidst widespread shortages of Rho(D) immune globulin therapy (RhIg) across the United States. Natera's test, capable of being conducted as early as nine weeks into gestation, assesses the fetal RhD status using blood samples from pregnant patients. This includes analysis of intricate pseudogene and RhD-CE-D hybrid variants.
  • April 2023: Mediclinic launched safe, non-invasive prenatal testing (NIPT) for expectant parents, expanding its DNA-based diagnostic and clinical interpretation services. This launch comes on the heels of Mediclinic's earlier introduction of Ancestry testing services.

Non-invasive Prenatal Testing Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Babies with Chromosomal Disorders Owing to Increasing Number of Late Pregnancies
    • 4.2.2 Increasing Demand for Early and Non-Invasive Fetal Diagnosis
    • 4.2.3 Favorable Reimbursement Policies
  • 4.3 Market Drivers
    • 4.3.1 Lack of Skilled Professionals
    • 4.3.2 Stringent Regulations and Ethical Concerns
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD Billion)

  • 5.1 By Component
    • 5.1.1 Instruments
    • 5.1.2 Kits and Reagents
    • 5.1.3 Services
  • 5.2 By Application
    • 5.2.1 Down Syndrome (Trisomy 21)
    • 5.2.2 Edwards Syndrome (Trisomy 18)
    • 5.2.3 Patau Syndrome (Trisomy 13)
    • 5.2.4 Turner Syndrome
    • 5.2.5 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Diagnostic Labs
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BGI
    • 6.1.2 Eurofins Scientific
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Invitae Corporation
    • 6.1.5 Illumina Inc.
    • 6.1.6 Natera Inc.
    • 6.1.7 PerkinElmer Inc.
    • 6.1.8 Centogene NV
    • 6.1.9 MedGenome Labs Ltd
    • 6.1.10 Myriad Womens Health Inc.
    • 6.1.11 Qiagen
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Non-invasive Prenatal Testing Industry Segmentation

As per the scope of the report, non-invasive prenatal testing (NIPT), which is also called non-invasive prenatal screening (NIPS), is a method for determining the risk that the fetus will be born with certain genetic abnormalities. It is based on analysis of cell free DNA (cfDNA) in maternal blood. This testing analyzes small DNA fragments circulating in a pregnant woman's blood. NIPT analyzes the genetic information contained in this DNA to screen for a number of abnormalities.


The non-invasive prenatal testing market is segmented into components, applications, end users and geography. By component, the market is segmented into instruments, kits and reagents, and services. By application, the market is segmented into Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), turner syndrome, and other applications. By end user, the market is segmented into hospitals and diagnostic labs. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The report offers the value (in USD Billion) for the above segments.

By Component Instruments
Kits and Reagents
Services
By Application Down Syndrome (Trisomy 21)
Edwards Syndrome (Trisomy 18)
Patau Syndrome (Trisomy 13)
Turner Syndrome
Other Applications
By End User Hospitals
Diagnostic Labs
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Non-invasive Prenatal Testing Market Research FAQs

What are the key players in the non-invasive prenatal testing market?

Key market players are BGI, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., Qiagen, Laboratory Corp. of America Holdings, and Quest Diagnostics, among others

What is the market size for Non-Invasive Prenatal Testing?

The global non-invasive prenatal testing market size is estimated at USD 3.90 billion in 2025 and is expected to reach USD 7.35 billion by 2030, growing at a CAGR of 13.50% during the forecast period (2025-2030).

What are the current trends in the non-invasive prenatal testing market?

Current trends underscore the rising adoption and technological evolution of non-invasive prenatal testing (NIPT). Originally focused on detecting trisomies 13, 18, and 21, NIPT is now broadening its scope to encompass microdeletions and autosomal dominant diseases, all while showcasing high sensitivity and minimal false positive rates. This method leverages cell-free fetal DNA extracted from maternal blood. Recent innovations, such as trophoblast retrieval from the cervix (TRIC), promise advantages over conventional techniques.

What are the challenges facing the non-invasive prenatal testing market players?

Key challenges faced by the market are a lack of skilled labor and stringent regulatory and ethical concerns.

What are the emerging technologies in non-invasive prenatal testing?

Emerging technologies in non-invasive prenatal testing (NIPT) are whole genome sequencing, single molecule sequencing, artificial intelligence etc, which focus on enhancing accuracy and expanding the range of detectable conditions.